AstraZeneca : ENHERTU Combination Approved In US For 1st-Line HER2-Positive Metastatic Breast Cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for first-line treatment of adult patients with unresectable or metastatic HER2‑positive breast cancer, triggering a $150 million milestone payment from AstraZeneca to Daiichi Sankyo and with U.S. ENHERTU sales recognized by Daiichi. ENHERTU, a HER2-directed DXd ADC discovered by Daiichi and co‑developed/commercialized with AstraZeneca, received the approval via the FDA’s Real‑Time Oncology Review and was also reviewed under Project Orbis; the same regimen is under review by Swissmedic and Singapore’s HSA with other international filings pending. The decision expands the drug’s addressable market into first‑line metastatic disease and could materially boost revenues for the partners if additional regulatory approvals follow internationally.

Analysis

The FDA approved AstraZeneca and Daiichi Sankyo’s ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, a decision issued under the FDA’s Real-Time Oncology Review. AstraZeneca will make a $150 million milestone payment to Daiichi Sankyo tied to this indication, and the article states that U.S. ENHERTU sales are recognized by Daiichi Sankyo.

The approval expands ENHERTU into the first-line metastatic HER2 setting, materially enlarging its addressable market and creating immediate near-term revenue recognition for Daiichi via the milestone plus U.S. sales. ENHERTU is a DXd antibody–drug conjugate discovered by Daiichi and co-developed/commercialized with AstraZeneca, so the partners’ ultimate revenue capture will depend on commercial execution and any profit‑share arrangements.

The submission was also reviewed under Project Orbis and is under review by Swissmedic and Singapore’s HSA, indicating an expedited pathway for additional international approvals that would act as further catalysts. Primary risks to monitor are U.S. commercial launch execution, payer reimbursement and the outcomes of ongoing international regulatory reviews; initial sales and coverage data will be key near-term indicators.

Key Decisions for Investors

• Consider increasing exposure to Daiichi Sankyo to reflect the immediate $150 million milestone and U.S. sales recognition, while awaiting the company’s sales reporting and guidance to confirm sustainable revenue uplift.
• For AstraZeneca, maintain or modestly add exposure to capture expanded first‑line HER2 franchise potential but factor in the $150 million milestone outflow and monitor commercial launch metrics and payer coverage.
• Treat Swissmedic, Singapore HSA and other Project Orbis outcomes as binary near‑term catalysts and be prepared to re‑rate positions if additional approvals are granted.
• Manage downside risk by monitoring initial U.S. uptake, reimbursement decisions and competitive dynamics; consider position sizing or hedges until early sales and payer data validate market adoption.